An observational study in Primary Hypercholesterolemiia and Mixed Dyslipidemia, sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. Active, not recruiting at 163 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (part of Daiichi Sankyo) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Dyslipidemias with a site in Italy — 7 open to participants now, 12 under way, 3 of them phase 3. Dyslipidemias · Italy.
Among the 51 studies in Dyslipidemias with a site in Italy, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2025, is one of 11 observational ones, reaches primary completion later than 6 of the 11 other live ones, and was the 43rd registered.
1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →7 of the 51 studies in Dyslipidemias with a site in Italy are open now. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 20 more countries
Ages 6–11
University of Pavia · Sites in Italy
Ages 18–70
University of Pavia · Sites in Italy
Ages 18+
IRCCS Eugenio Medea · Sites in Italy
Ages 5–17
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 19 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 660 across 231 observational studies indexed under Dyslipidemias.
Median enrollment 153 across the 40 interventional studies, 387 across the 11 observational. Of the 34 that completed or were terminated, 13 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, one of the names counted as Daiichi Sankyo. Under that name alone:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
Daiichi Sankyo has 6 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
3 of the studies in Dyslipidemias with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07206875IRCCS San RaffaeleObservational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders | 2026-11 |
| NCT06686615Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyA Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies in Dyslipidemias with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.
The aim of the current study is to evaluate the effectiveness and safety of bempedoic acid combined with ezetimibe and either atorvastatin or rosuvastatin (hereafter defined as triple therapy) in a real-world clinical setting. No drug will be administered during this observational study.
The primary objective of the study is to evaluate the effectiveness of the triple therapy in terms of LDL-C reduction at 8 weeks.
The secondary objectives will include the following:
Prospective data from routine clinical practice will be collected over the course of 1 year involving approximately 2000 patients across approximately 200 sites in Europe (Germany, Italy, Spain, Austria, and Belgium) treated by both specialized and non-specialized physicians in hospital and office-based settings.
Key Inclusion Criteria:
Patients treated with:
6) Initiation of triple therapy within a maximum of four weeks prior to inclusion 7) An untreated LDL-C value must be available within 5 years prior to the start of the triple therapy. Untreated means that the LDL-C value is not influenced by any lipid lowering therapy at the time of blood collection. Time window for not being treated as specified in the protocol.
8) No exist according to the SmPC of bempedoic acid, the respective statin and ezetimibe as per physicians' assessment 9) No concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is possible) 10) > 1 -year
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients who have been diagnosed with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia treated with bempedoic acid in combination with ezetimibe and either rosuvastatin or atorvastatin (ie, triple therapy) and will be followed for up to 1 year after initiation of triple therapy. A direct comparison between rosuvastatin and atorvastatin is not planned, only an assessment of triple therapy on LDL-C change in patients with primary hypercholesterolaemia.
Drug: Bempedoic acid · Drug: Ezetimibe · Drug: Rosuvastatin · Drug: Atorvastatin
No drug was administered in this observational study.
No drug was administered in this observational study.
No drug was administered in this observational study.
No drug was administered in this observational study.
Relative LDL-C change between untreated and 8 week after triple therapy start
LDL-C will be assessed using a standard lipid panel blood test,
Time frame: Baseline to 8 weeks after initiation of triple therapy
Proportion of patients at ESC/EAS 2019 dyslipidemia guideline goal at 8 weeks and 1 year
The 2019 EAS/ESC guidelines recommend treatment targets of at least a 50% reduction from baseline LDL-C levels and an LDL-C concentration below 1.8 mmol/L for patients at high and 1.4 mmol/l for patients at very high cardiovascular risk.
Time frame: Baseline to 1 year after initiation of triple therapy
Relative LDL-C change between untreated and 1 year after triple therapy start
LDL-C will be assessed using a standard lipid panel blood test,
Time frame: From any prior LMT exposure to 1 year after initiation of triple therapy
Relative LDL-C change between pre-bempedoic acid/pre-FDC initiation and 8 weeks after triple therapy start
LDL-C will be assessed using a standard lipid panel blood test,
Time frame: From pre-bempedoic acid/pre-FDC initiation to 8 weeks after initiation of triple therapy
Relative LDL-C change between pre-bempedoic acid/pre-FDC initiation and 1 year after triple therapy start
LDL-C will be assessed using a standard lipid panel blood test,
Time frame: From pre-bempedoic acid/pre-FDC initiation to 1 year after initiation of triple therapy
Relative change in laboratory values between triple therapy start and 8 weeks and 1 year thereafter
Labs will be assessed using a standard panel blood test,
Time frame: Baseline to 1 year after initiation of triple therapy
Patient and physician reported adherence at 8 weeks and 1 year after triple therapy start
Adherence will be judged by the physician/patient.
Time frame: Baseline to 1 year after initiation of triple therapy
Incidence of adverse events under triple therapy exposure
Adverse events are defined as any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Baseline to 1 year after initiation of triple therapy
Proportion of patients with MACE-3 and MACE-4 events
MACE-3 and MACE-4 events will consist of non-fatal MI, non-fatal stroke, CV-death, and coronary revascularization (for MACE-4 only).
Time frame: Baseline to 1 year after initiation of triple therapy
Showing the first 100 of 163 sites across 5 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 29 months after the start.
Of 34 industry-sponsored observational studies under Dyslipidemias, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's planned 29 months is close to that.
Counting every sponsor, half of 90 studies reached it within 40 months; a quarter within 23 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company →